Omlin, A. G., Graff, J. N., Hoimes, C. J., Tagawa, S. T., Hwang, C., Kilari, D., … Antonarakis, E. S. (2020). 623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update. In Annals of Oncology (Vol. 31, pp. S514–S515). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.882

Omlin, A. G., J. N. Graff, C. J. Hoimes, S. T. Tagawa, C. Hwang, D. Kilari, A. J. Ten Tije, et al. “623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update.” In Annals of Oncology, 31:S514–15. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.882.

Omlin AG, Graff JN, Hoimes CJ, Tagawa ST, Hwang C, Kilari D, et al. 623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update. In: Annals of Oncology. Elsevier BV; 2020. p. S514–5.

Omlin, A. G., et al. “623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update.” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S514–15. Crossref, doi:10.1016/j.annonc.2020.08.882.

Omlin AG, Graff JN, Hoimes CJ, Tagawa ST, Hwang C, Kilari D, Ten Tije AJ, McDermott R, Vaishampayan UN, Elliott T, Gerritsen WR, Wu H, Kim J, Schloss C, de Bono JS, Antonarakis ES. 623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update. Annals of Oncology. Elsevier BV; 2020. p. S514–S515.